What the research shows
SURMOUNT-1 randomized 2,539 adults with obesity or overweight and a weight-related condition, excluding people with diabetes. Mean weight change at 72 weeks ranged from −15.0% to −20.9% across tirzepatide groups and was −3.1% with placebo. SURMOUNT-1 randomized trial.
The U.S. Zepbound label describes injectable tirzepatide for specified weight-management populations and for moderate-to-severe obstructive sleep apnea in adults with obesity. Each indication has its own clinical evidence. Zepbound prescribing information.
Documented formats
Zepbound is supplied as an injectable solution in labeled pen and vial presentations. The specific presentation determines the labeled amount and concentration.
Testing and purity
When checking a product record, match the full brand, presentation, concentration and label identifier. Strength per container and concentration per milliliter are separate measurements.
How to read a batch reportQuestions about Tirzepatide
Did SURMOUNT-1 compare tirzepatide with semaglutide?
It compared tirzepatide with placebo. The reported percentages apply to that comparison.
What does the percentage weight change describe?
Each percentage summarizes the average change relative to starting body weight in one trial group. Individual participants had a range of outcomes.